The management of diabetes mellitus is one of the most complex challenges facing modern healthcare systems. Among the many complications that arise from poorly controlled blood glucose levels, peripheral neuropathy stands out as both common and potentially devastating. It affects the sensory nerves of the extremities, most frequently the feet, and can lead to ulceration, infection, and ultimately amputation if left undetected. For decades, clinicians have relied on a variety of tests to assess peripheral sensation in diabetic patients, ranging from the sophisticated to the unwieldy. The Ipswich Touch Test, developed in the early 2010s at Ipswich Hospital in the United Kingdom, represents something of a quiet revolution in this space — a test so simple that it requires no equipment whatsoever, yet carries genuine clinical validity and the potential to transform routine diabetic foot screening.
Origins and Development
The Ipswich Touch Test was developed by Dr. Gerry Rayman and colleagues at Ipswich Hospital NHS Trust in Suffolk, England. Published in 2011 in the journal Diabetes Care, the test emerged from a practical frustration that many clinicians will recognise: the standard tools used for detecting peripheral neuropathy, particularly the 10-gram Semmes-Weinstein monofilament, were often unavailable in primary care settings, time-consuming to administer correctly, and subject to significant variability based on operator technique and equipment condition. The monofilament, while considered a gold standard for many years, could buckle unpredictably, required calibration, and could be misapplied by less experienced practitioners. What was needed, Rayman and his team argued, was something reproducible, accessible, and quick enough to be integrated into the ordinary flow of a clinical consultation.
The test they devised is elegantly straightforward. The clinician lightly touches the tips of the first, third, and fifth toes of both feet with the index finger for one to two seconds. The patient, with eyes closed, is asked to indicate whether they can feel each touch. If a patient is unable to feel the touch at two or more sites, the test is considered to indicate significant peripheral neuropathy, placing them at elevated risk of foot ulceration. No equipment is required. No calibration is necessary. The test takes under a minute to perform.
Clinical Validity and Evidence Base
The critical question any new diagnostic tool must answer is whether it performs reliably in comparison to established methods. The original 2011 study compared the Ipswich Touch Test directly against the 10-gram monofilament test in a cohort of diabetic patients attending an outpatient clinic. The results were encouraging. The touch test demonstrated a sensitivity of around 78% and specificity of approximately 91% for detecting neuropathy at the level of risk identified by the monofilament. Subsequent studies have broadly confirmed these findings, with some reporting slightly varying sensitivity and specificity depending on the population studied and the clinical setting. While it is not perfect — no screening tool is — its performance is considered sufficient for routine risk stratification, particularly in primary care, where the alternative may often be no testing at all.
A key strength of the Ipswich Touch Test lies in its inter-rater reliability. Because it depends on light fingertip touch rather than a calibrated instrument, one might expect significant variation between different examiners. In practice, studies have shown that reliability between practitioners is acceptable, particularly when clinicians receive basic instruction in the method. This places it in a favourable position compared to the monofilament, which can show considerable variability based on how many times it has been used and whether the operator allows it adequate recovery time between applications.
Practical Application in Primary Care
The greatest argument in favour of the Ipswich Touch Test is not that it is better than existing tools in controlled clinical conditions, but that it is vastly more likely to actually be used. Diabetic foot complications are responsible for enormous morbidity and healthcare costs globally. The International Diabetes Federation estimates that a lower limb is lost to diabetes every thirty seconds worldwide. A substantial proportion of these amputations are preceded by a foot ulcer that could have been identified earlier if regular foot screening had taken place. In resource-limited settings, or simply in the ordinary pressures of a busy general practice, the barrier to performing a monofilament test — finding the equipment, checking its condition, following the correct protocol — is often enough to mean the test is skipped entirely.
The Ipswich Touch Test removes this barrier almost entirely. A general practitioner, practice nurse, or community health worker need only their own finger and a cooperative patient to screen for significant peripheral neuropathy. This has made it particularly attractive in low- and middle-income countries where specialist diabetic foot services and diagnostic equipment may be scarce, but where the burden of diabetic complications is rapidly growing. Several studies from India, sub-Saharan Africa, and parts of Southeast Asia have explored the test’s utility in these contexts, generally with positive findings regarding feasibility and acceptability.
Limitations and Appropriate Use
Despite its considerable advantages, the Ipswich Touch Test is not without limitations. Its sensitivity, while adequate for a screening tool, means that a proportion of patients with clinically relevant neuropathy will not be identified. It should therefore be understood as a screening instrument rather than a definitive diagnostic test. Patients who screen positive, or who present with other risk factors for foot complications, should be referred for more comprehensive podiatric or neurological assessment. The test also relies on subjective patient reporting and consistent examiner technique, both of which can introduce variability, albeit less than might be expected.
There is also the question of what happens after an abnormal result. A positive screen is only valuable if it triggers an appropriate clinical response — enhanced foot care education, referral to podiatry, more frequent review, and optimisation of glycaemic control. The test’s utility depends entirely on the systems in place to act on its findings.
The Ipswich Touch Test occupies an important and underappreciated niche in diabetic care. It is not a perfect test, and it was never intended to be. Its value lies in its capacity to bring basic neuropathy screening to settings and consultations where nothing else would otherwise occur. By reducing the barrier to examination to virtually zero, it creates the opportunity to identify at-risk patients who might otherwise progress to ulceration and amputation undetected. In a condition as prevalent and consequential as diabetes, that kind of accessible, practical innovation deserves to be far more widely adopted than it currently is.